Alle Storys
Folgen
Keine Story von IsoTis OrthoBiologics mehr verpassen.

IsoTis OrthoBiologics

IsoTis Reports Status of Merger Vote

Irvine, California (ots/PRNewswire)

- Less than 100,000 Additional "FOR" Votes Required for Integra
Merger
IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company,
today reported that less than 100,000 votes "FOR" are needed to
approve the acquisition of IsoTis by Integra LifeSciences Holdings
Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and
plan of merger dated as of August 6, 2007.
Today's special meeting of stockholders will remain open
throughout the day to allow for additional votes to be cast. If
insufficient votes are cast in favor of the Integra merger at today's
meeting, IsoTis will adjourn the meeting to October 30, 2007.
Of the approximately 3.7 million shares present in person or by
proxy at today's meeting, approximately 3.5 million shares voted
"for" the merger with Integra, representing approximately 94.4% of
the votes cast to date and approximately 49.0% of all outstanding
shares at the record date.
The IsoTis Board of Directors continues to believe unanimously
that the interests of IsoTis' stockholders are best served by the
acquisition by Integra, and that there are no feasible alternatives
for the company and its stockholders. If IsoTis is unable to obtain
the vote necessary to approve the proposed transaction, the company
believes it will have to seek bankruptcy protection.
About IsoTis
IsoTis is an orthobiologics company that develops, manufactures
and markets proprietary products for the treatment of musculoskeletal
diseases and disorders. IsoTis' current orthobiologics products are
bone graft substitutes that promote the regeneration of bone and are
used to repair natural, trauma-related and surgically-created defects
common in orthopedic procedures, including spinal fusions. IsoTis'
current commercial business is highlighted by its Accell line of
products, which the company believes represents the next generation
in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have
reached a definitive agreement to create a global orthobiologics
leader. The combination would create a comprehensive orthobiologics
portfolio, one of the largest sales organizations focused on
orthobiologics in the US, and multiple cross-selling opportunities.
The transaction is subject to approval of IsoTis' stockholders, as
well as other closing conditions and approvals. Upon closing, IsoTis
will become a wholly-owned subsidiary of Integra and Integra will be
one of the largest companies in the world focused on advanced
technology in orthobiologics.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, including those that refer to
management's plans and expectations for, among other things, future
operations, strategies, prospects, performance and financial
condition and IsoTis' proposed acquisition by Integra. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "may,"
"will," "might," "could," "would," "continues," "estimates,"
"intends," "pursues," "projects," "goals," "targets" or the negative
or other variations thereof and other words of similar meaning are
intended to identify such forward-looking statements. One can also
identify them by the fact that they do not relate strictly to
historical or current facts. Such statements are based on the current
expectations and projections of the management of IsoTis only. Undue
reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be
affected by factors that are beyond the control of IsoTis. Actual
results could differ materially from current expectations and
projections. Any forward-looking statements are made pursuant to the
Private Securities Litigation Reform Act of 1995 and, as such, speak
only as of the date made. IsoTis undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
A special stockholder meeting was convened on October 11, 2007,
adjourned to October 23, 2007 and again adjourned to October 26, 2007
to obtain stockholder approval of the proposed transaction. IsoTis
has filed with the Securities and Exchange Commission and distributed
to its stockholders a definitive proxy statement and other relevant
documents in connection with the special stockholder meeting for the
proposed transaction. IsoTis stockholders are urged to read the
definitive proxy statement and other relevant materials when they
become available because they will contain important information
about IsoTis, Integra and the proposed transaction. Investors may
obtain a free copy of these materials and other documents filed by
IsoTis with the Securities and Exchange Commission at the SEC's
website at http://www.sec.gov, at IsoTis' website at
http://www.isotis.com or by sending  a written request to IsoTis at 2
Goodyear, Irvine, California 92618,  Attention: Chief Financial
Officer.
IsoTis and its directors, executive officers and certain other
members of management and employees may be deemed to be participants
in soliciting proxies from its stockholders in favor of the proposed
merger. Information regarding the persons who may, under the rules of
the SEC, be considered to be participants in the solicitation of
IsoTis' stockholders in connection with the proposed transaction will
be set forth in IsoTis' revised definitive proxy statement for its
special meeting. Additional information regarding these individuals
and any interest they have in the proposed transaction is set forth
in the revised definitive proxy statement when it is filed with the
SEC.
For information contact:
    Rob Morocco, CFO,
    +1-949-855-7155
     robert.morocco@isotis.com
    Hans Herklots, Director IR
    +1-949-855-7195 or +41-21-620-6011
     hans.herklots@isotis.com

Contact:

Rob Morocco, CFO, +1-949-855-7155, robert.morocco@isotis.com; Hans
Herklots, Director IR, +1-949-855-7195 or +41-21-620-6011,
hans.herklots@isotis.com

Weitere Storys: IsoTis OrthoBiologics
Weitere Storys: IsoTis OrthoBiologics
  • 24.10.2007 – 16:24

    IsoTis Adjourns Special Meeting to October 26, 2007

    Irvine, California (ots/PRNewswire) - - Less Than 350,000 Additional Votes "FOR" Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders again, to October 26, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement ...

  • 16.10.2007 – 09:00

    IsoTis Reports Interim Results of Vote for Integra Merger

    Irvine, California (ots/PRNewswire) - - Conference Calls to Answer Questions About Stockholder Meeting October 23 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the interim tabulation results of the special stockholders meeting held on October 11, 2007 and adjourned to October 23, 2007. Prior to October 11, 2007, approximately 2,555,000 shares, 36 percent of the shares ...

  • 11.10.2007 – 23:13

    IsoTis Adjourns Special Meeting to October 23, 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders it called to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The special meeting of stockholders was held at ...